← Eichor
Study identifier: NCT05680220 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

40 Hz Light Neurostimulation for Patients With Depression (FELIX)

Condition: Major Depressive Disorder · Treatment Resistant Depression  ·  Sponsor: Klaus Martiny

PhaseNA
Planned participants60
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

Recent research in mice models of Alzheimer's disease (AD) has demonstrated that one hour per day of exposure to 40 Hz flickering light therapy can halt the disease's progression, and improve cognition and memory. Moreover, recent data suggest that 40 Hz light stimulation may induce neuroplasticity and reduce neuroinflammation. In this study, the investigators aim to evaluate the antidepressant effects of 40 Hz light stimulation in Major Depressive Disorder (MDD). Patients will be exposed to 40 Hz invisible spectral flickering light (active setting) or continuous non-flickering white light (sham setting) in a home setting for 1 hour each day.

This description comes directly from the study's public registry record.

Talk to the study team

Klaus Martiny  ·  +45 38 64 71 00  ·  klaus.martiny@regionh.dk

Malina Ploug Larsen  ·  malina.ploug.larsen@regionh.dk

Always discuss trial participation with your own doctor first.

Locations (1)

Mental Health Centre CopenhagenCopenhagen, Denmark, DenmarkRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05680220